The recent 13% price drop in Hims & Hers Health (HIMS) presents a high-conviction buying opportunity, as the sell-off over a one-time $28 million write-off ignores strong fundamental growth. The company is seeing massive momentum in the weight-loss sector, recording 125,000 Wegovy shipments in just six weeks and generating high-margin recurring revenue through a $149/month prescription fee. Investors should look toward 2026 growth, which is expected to hit the high 30% range—outperforming management’s conservative guidance—driven by the upcoming Eucalyptus acquisition and international expansion. HIMS is successfully transitioning into a major distribution partner for big pharma and diagnostic testing, backed by a stock buyback program that provides a valuation floor. Capitalize on this "cash pay" healthcare leader as it integrates AI medical agents and proprietary data to scale its personalized medicine platform globally.

Hims & Hers Health, Inc. (HIMS)

The stock experienced a significant 13% price drop following the Q1 earnings call, which the analyst attributes to market overreaction regarding a $28 million write-off and a shift in focus toward heavy long-term investment rather than immediate margin expansion. Despite the price action, the analyst maintains a highly bullish outlook based on fundamental growth and strategic positioning.

• The $28 Million Write-off: The company wrote off $28 million related to compounding manufacturing equipment. While the market reacted negatively, the analyst views this as a strategic "cleaning of the books" that reduces future taxes and allows the company to pivot toward branded GLP-1s and other high-growth areas. • GLP-1 Momentum: * Wegovy (Novo Nordisk): Reported 125,000 shipments in the first six weeks alone. * Unbranded GLP-1s: Currently at a run rate of 100,000 prescriptions per month. * Revenue Model: Hims earns a $149/month prescription fee, which the analyst describes as "literally pure margin" (estimated at 80%+). • AI Integration: Hims has built an AI team of over 30 people. The goal is to use 10 years of proprietary data from 2.6 million subscribers to create specialized "AI medical agents" (e.g., specialists for specific age groups or conditions) to provide a "doctor in your pocket" experience. • International Expansion: The acquisition of Eucalyptus is expected to close within two months, potentially adding significantly to the Annual Recurring Revenue (ARR) and expanding the footprint in Australia. • Future Product Pipeline: * Peptides: Plans to launch, though the company is taking a "slow but best" approach. * Painless Needles/Labs: Utilizing the Juvio acquisition to offer "labs by mail," reducing friction for diagnostic testing. * Wearables: Intentions to integrate with Apple/Android health data and potentially launch proprietary hardware.

Takeaways

• Buy Opportunity: The analyst views the 13% drop as a disconnect between market sentiment and business fundamentals, suggesting the stock is "too cheap" based on an EV/Gross Profit/Revenue growth metric. • Growth Guidance: Management guided for 19%–28% growth in 2026. The analyst believes this is "sandbagged" (intentionally conservative) and expects growth in the high 30% range once the Eucalyptus acquisition and GLP-1 momentum are fully accounted for. • Platform Shift: Hims is transitioning from a simple telehealth provider to a distribution partner for major pharma (like Grail's cancer tests), which could create a high-margin revenue-share model. • Capital Allocation: The company has a stock buyback program in place; the analyst suggests that if the market continues to "disrespect" the valuation, aggressive buybacks could be a catalyst for recovery.

GLP-1 Weight Loss Medications (Wegovy / Zepbound)

The transcript highlights the massive scale at which Hims is distributing these high-demand medications, both in branded and compounded forms.

• Distribution Power: Hims is positioning itself as the preferred "cash pay" channel for innovative drugs. • Volume: The mention of 125,000 Wegovy shipments in six weeks indicates that Hims is capturing a significant share of the telehealth weight-loss market.

Takeaways

• High Margin Service: Even when Hims doesn't manufacture the drug, the $149 monthly service fee provides a recurring, high-margin revenue stream that is less dependent on drug supply chains than traditional pharmacies.

Investment Themes & Sectors

Telehealth & Personalized Medicine

• Theme: The shift from "one-size-fits-all" healthcare to data-driven, personalized plans. • Insight: Success in this sector is increasingly dependent on proprietary data flywheels. Companies with years of patient interaction data (like Hims) have a competitive advantage in training AI to improve health outcomes.

The "Cash Pay" Healthcare Model

• Theme: Moving away from insurance-reimbursed healthcare to direct-to-consumer (DTC) cash payments. • Insight: This model allows for faster international scaling (copy-pasting the US model to the UK, Australia, etc.) because it avoids the complexities of local insurance regulations.

AI in Healthcare

• Theme: AI agents replacing or augmenting traditional consultations. • Insight: The analyst highlights that AI experts are drawn to companies with massive datasets. Hims' 2.6 million monthly data points create a "flywheel" that improves the product, which in turn attracts more users and better talent.